Fetal therapy, ethics and public policies

Area of Science:

• Medical Ethics
• Fetal Medicine
• Bioethics

Background:

• The first generation of experimental fetal therapy presented novel ethical dilemmas.
• Key issues included risk/benefit analysis, patient selection, informed consent, and managing twin pregnancies.
• Refusal of established fetal therapies also posed ethical questions.

Purpose of the Study:

• To review the evolution of ethical problems in early experimental fetal therapy.
• To discuss the prevailing approaches to these ethical challenges.
• To examine ethical and public policy implications of lacking federal support for fetal research and therapy.

Main Methods:

• Literature review and ethical analysis of historical cases and policies.
• Identification of ethical principles relevant to fetal interventions.
• Argumentation for increased federal support for fetal research, including gene therapy.

Main Results:

• Identified recurring ethical problems in experimental fetal therapy: risk/benefit assessment, case selection, informed consent, twin pregnancies, and therapy refusal.
• Highlighted the absence of U.S. federal support for critical areas like fetal diagnosis, therapy, and human embryo research.
• Found contradictions between ethical principles supporting early intervention and current research funding limitations.

Conclusions:

• There is an ethical imperative to develop and support fetal therapies, including experimental gene therapy, to treat human suffering.
• Increased U.S. federal support is crucial for advancing fetal diagnosis, therapy, and related research.
• Addressing ethical challenges and policy gaps is essential for the responsible progression of fetal medicine.